424 related articles for article (PubMed ID: 27854122)
1. The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
Shinno K; Kurokawa K; Kozai S; Kawamura A; Inada K; Tokushige H
Curr Eye Res; 2017 May; 42(5):748-753. PubMed ID: 27854122
[TBL] [Abstract][Full Text] [Related]
2. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans.
Takamura Y; Tomomatsu T; Matsumura T; Takihara Y; Kozai S; Arimura S; Yokota S; Inatani M
J Ocul Pharmacol Ther; 2015 Jun; 31(5):282-5. PubMed ID: 25918904
[TBL] [Abstract][Full Text] [Related]
3. Ocular and systemic pharmacokinetics of brimonidine and brinzolamide after topical administration in rabbits: comparison between fixed-combination and single-drug formulations.
Suzuki G; Kunikane E; Shigemi W; Shinno K; Kozai S; Kurata M; Kawamura A
Curr Eye Res; 2021 Mar; 46(3):380-386. PubMed ID: 32706598
[TBL] [Abstract][Full Text] [Related]
4. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes.
Acheampong AA; Shackleton M; John B; Burke J; Wheeler L; Tang-Liu D
Drug Metab Dispos; 2002 Apr; 30(4):421-9. PubMed ID: 11901096
[TBL] [Abstract][Full Text] [Related]
5. Effect of Solution pH on Distribution of Ophthalmically Administered Brimonidine in Posterior Ocular Tissues in Pigmented Rabbits.
Shinno K; Kurokawa K; Kozai S; Kawamura A; Inada K; Tokushige H
Ophthalmol Ther; 2019 Jun; 8(2):271-277. PubMed ID: 30891685
[TBL] [Abstract][Full Text] [Related]
6. Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study.
Orii Y; Kunikane E; Yamada Y; Morioka M; Iwasaki K; Arimura S; Mizuno A; Inatani M
PLoS One; 2022; 17(12):e0277313. PubMed ID: 36454807
[TBL] [Abstract][Full Text] [Related]
7. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.
Chastain JE; Sanders ME; Curtis MA; Chemuturi NV; Gadd ME; Kapin MA; Markwardt KL; Dahlin DC
Exp Eye Res; 2016 Apr; 145():58-67. PubMed ID: 26474497
[TBL] [Abstract][Full Text] [Related]
8. Vitreous concentration of topically applied brimonidine-purite 0.15%.
Kent AR; King L; Bartholomew LR
J Ocul Pharmacol Ther; 2006 Aug; 22(4):242-6. PubMed ID: 16910864
[TBL] [Abstract][Full Text] [Related]
9. Ocular pharmacokinetics profile of different indomethacin topical formulations.
Bucolo C; Melilli B; Piazza C; Zurria M; Drago F
J Ocul Pharmacol Ther; 2011 Dec; 27(6):571-6. PubMed ID: 22059858
[TBL] [Abstract][Full Text] [Related]
10. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.
Acheampong AA; Shackleton M; Tang-Liu DD
Drug Metab Dispos; 1995 Jul; 23(7):708-12. PubMed ID: 7587958
[TBL] [Abstract][Full Text] [Related]
11. Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown.
Shen J; Durairaj C; Lin T; Liu Y; Burke J
Invest Ophthalmol Vis Sci; 2014 Feb; 55(2):1056-66. PubMed ID: 24448267
[TBL] [Abstract][Full Text] [Related]
12. Comparison of concentration-time profiles of levobunolol and timolol in anterior and posterior ocular tissues of albino rabbits.
Acheampong AA; Breau A; Shackleton M; Luo W; Lam S; Tang-Liu DD
J Ocul Pharmacol Ther; 1995; 11(4):489-502. PubMed ID: 8574812
[TBL] [Abstract][Full Text] [Related]
13. Ocular and Systemic Pharmacokinetics of Brimonidine and Timolol After Topical Administration in Rabbits: Comparison Between Fixed-Combination and Single Drugs.
Suzuki G; Kunikane E; Shinno K; Kozai S; Kurata M; Kawamura A
Ophthalmol Ther; 2020 Mar; 9(1):115-125. PubMed ID: 31953739
[TBL] [Abstract][Full Text] [Related]
14. Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine.
Kim SN; Ko SA; Park CG; Lee SH; Huh BK; Park YH; Kim YK; Ha A; Park KH; Choy YB
Mol Pharm; 2018 Aug; 15(8):3143-3152. PubMed ID: 30020792
[TBL] [Abstract][Full Text] [Related]
15. Route of penetration of topically instilled nipradilol into the ipsilateral posterior retina.
Mizuno K; Koide T; Shimada S; Mori J; Sawanobori K; Araie M
Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2839-47. PubMed ID: 19218605
[TBL] [Abstract][Full Text] [Related]
16. Iganidipine, a new water-soluble Ca2+ antagonist: ocular and periocular penetration after instillation.
Ishii K; Matsuo H; Fukaya Y; Tanaka S; Sakaki H; Waki M; Araie M
Invest Ophthalmol Vis Sci; 2003 Mar; 44(3):1169-77. PubMed ID: 12601046
[TBL] [Abstract][Full Text] [Related]
17. Influence of dosage form on the intravitreal pharmacokinetics of diclofenac.
Durairaj C; Kim SJ; Edelhauser HF; Shah JC; Kompella UB
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4887-97. PubMed ID: 19516015
[TBL] [Abstract][Full Text] [Related]
18. Ocular Distribution of Brimonidine and Brinzolamide after Topical Instillation of a 0.1% Brimonidine Tartrate and 1% Brinzolamide Fixed-Combination Ophthalmic Suspension: An Interventional Study.
Orii Y; Kunikane E; Yamada Y; Morioka M; Iwasaki K; Arimura S; Mizuno A; Inatani M
J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445209
[TBL] [Abstract][Full Text] [Related]
19. Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma.
Chiang B; Kim YC; Doty AC; Grossniklaus HE; Schwendeman SP; Prausnitz MR
J Control Release; 2016 Apr; 228():48-57. PubMed ID: 26930266
[TBL] [Abstract][Full Text] [Related]
20. Vitreous concentration of topically applied brimonidine tartrate 0.2%.
Kent AR; Nussdorf JD; David R; Tyson F; Small D; Fellows D
Ophthalmology; 2001 Apr; 108(4):784-7. PubMed ID: 11297498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
